Psychotropic Medication Use in Children and Adolescents With Type 1 Diabetes

• Published in: JAMA network open 2023, Vol.6 (10), p.e2336621-e2336621
• Main Authors: Liu, Shengxin, Lagerberg, Tyra, Ludvigsson, Jonas F., Taylor, Mark J., Chang, Zheng, D’Onofrio, Brian M., Larsson, Henrik, Lichtenstein, Paul, Gudbjörnsdottir, Soffia, Kuja-Halkola, Ralf, Butwicka, Agnieszka
• Format: Article
• Language: English
• Subjects: Attention deficit hyperactivity disorder; Cohort analysis; Diabetes; Endocrinology and Diabetes; Endokrinologi och diabetes; Medicin och hälsovetenskap; Online Only; Original Investigation; Pediatrics; Psychotropic drugs; Teenagers; Tranquilizers; Trends
• ISSN: 2574-3805; 2574-3805
• DOI: 10.1001/jamanetworkopen.2023.36621

Importance Children and adolescents with type 1 diabetes (T1D) face elevated risks of psychiatric disorders. Despite their nonnegligible adverse effects, psychotropic medications are a common cost-effective approach to alleviating psychiatric symptoms, but evidence regarding their dispensation to children and adolescents with T1D remains lacking. Objective To examine the trends and patterns of psychotropic medication dispensation among children and adolescents with T1D in Sweden between 2006 and 2019. Design, Setting, and Participants This cohort study used data from multiple Swedish registers. The main study cohort included children and adolescents residing in Sweden from 2006 to 2019 and was followed up until the earliest of December 31, 2019, 18th birthday, emigration, or death. Data analyses were conducted from November 1, 2022, to April 30, 2023. Exposures Type 1 diabetes. Main Outcomes and Measures The primary outcomes were trends and patterns of psychotropic medication dispensation (including antipsychotics, antidepressants, anxiolytics, hypnotics, mood stabilizers, and medications for attention-deficit/hyperactivity disorder [ADHD]), psychotropic medication initiation, and history of neurodevelopmental and psychiatric diagnosis. Cumulative incidence curves and Cox proportional hazard models were used to estimate the aggregated incidence and hazard ratios of medication initiation after diabetes onset. Results Of 3 723 745 children and adolescents (1 896 199 boys [50.9%]), 13 200 (0.4%; 7242 boys [54.9%]) had T1D (median [IQR] age at diagnosis, 11.1 [7.6-14.7] years). Between 2006 and 2019, psychotropic medication dispensation increased from 0.85% (95% CI, 0.65%-1.10%) to 3.84% (3.11%-4.69%) among children and from 2.72% (95% CI, 2.15%-3.39%) to 13.54% (95% CI, 12.88%-14.23%) among adolescents with T1D, consistently higher than their peers without T1D. The most commonly dispensed medications included hypnotics, ADHD medications, anxiolytics, and selective serotonin reuptake inhibitors, and all exhibited increasing trends. For those with T1D, psychiatric care was the primary prescription source, and up to 50.1% of treatments lasted more than 12 months. In addition, children and adolescents with T1D showed higher cumulative incidence and hazard ratios of medication initiation after diabetes onset than their same-age and same-sex counterparts. Conclusions and Relevance This cohort study found an increasing trend in psychotropic medication dispensation a